Bicocca Open Archive

Logo unimib boa
CECCON, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.200
EU - Europa 1.650
AS - Asia 1.551
SA - Sud America 222
AF - Africa 40
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 6.667
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.115
SG - Singapore 626
CN - Cina 396
DE - Germania 339
IT - Italia 264
RU - Federazione Russa 226
HK - Hong Kong 220
IE - Irlanda 191
SE - Svezia 189
BR - Brasile 177
VN - Vietnam 122
GB - Regno Unito 119
UA - Ucraina 95
CA - Canada 70
FI - Finlandia 45
IN - India 42
AT - Austria 40
FR - Francia 40
PL - Polonia 27
JP - Giappone 25
TR - Turchia 24
AR - Argentina 23
ID - Indonesia 22
BE - Belgio 21
ZA - Sudafrica 20
BD - Bangladesh 19
DK - Danimarca 14
MX - Messico 12
ES - Italia 11
KR - Corea 11
NL - Olanda 10
IQ - Iraq 9
VE - Venezuela 7
LT - Lituania 6
MA - Marocco 6
IR - Iran 5
BG - Bulgaria 4
TN - Tunisia 4
CO - Colombia 3
EC - Ecuador 3
JO - Giordania 3
NP - Nepal 3
PE - Perù 3
PS - Palestinian Territory 3
PY - Paraguay 3
AM - Armenia 2
AZ - Azerbaigian 2
CL - Cile 2
DZ - Algeria 2
EU - Europa 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
MU - Mauritius 2
PK - Pakistan 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CH - Svizzera 1
EE - Estonia 1
EG - Egitto 1
HN - Honduras 1
KZ - Kazakistan 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
RO - Romania 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UZ - Uzbekistan 1
YE - Yemen 1
Totale 6.667
Salva come PNG Salva come JPEG
Città #
Ann Arbor 502
Singapore 328
Ashburn 293
Hong Kong 220
Frankfurt am Main 218
Fairfield 207
Chandler 206
Woodbridge 206
Dublin 188
Houston 156
Milan 142
Wilmington 137
Dearborn 107
New York 99
Jacksonville 90
Seattle 89
Cambridge 74
Beijing 64
Santa Clara 63
Los Angeles 62
Princeton 53
Nanjing 47
Ho Chi Minh City 41
Dallas 39
Vienna 36
Munich 29
Hefei 28
Shanghai 25
Altamura 24
Lawrence 23
Hanoi 22
Nanchang 22
São Paulo 21
Brussels 19
The Dalles 18
Warsaw 18
Buffalo 17
Jakarta 17
Montreal 17
Moscow 17
San Diego 17
Chicago 16
Tokyo 16
Lachine 15
Turku 15
Boardman 14
Brooklyn 13
Council Bluffs 13
Denver 13
Fremont 13
Guangzhou 12
Göttingen 12
Helsinki 12
Johannesburg 12
Orem 12
Rio de Janeiro 12
Toronto 12
London 10
Norwalk 10
Phoenix 10
Poplar 10
Chennai 9
Falls Church 9
Hangzhou 9
Lissone 9
Pune 9
Salt Lake City 9
Seoul 9
Andover 8
Atlanta 8
Ottawa 8
Shenyang 8
Tianjin 8
Chengdu 7
Da Nang 7
Edmonton 7
Jiaxing 7
Lodz 7
Manchester 7
Taizhou 7
Boston 6
Düsseldorf 6
Hebei 6
Kunming 6
Nuremberg 6
Romola 6
Ankara 5
Changsha 5
Haiphong 5
Jinan 5
Kent 5
Kiev 5
Kocaeli 5
Mexico City 5
Monza 5
San Francisco 5
San Jose 5
Stockholm 5
Taku 5
Zhengzhou 5
Totale 4.511
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 439
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 400
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 372
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 320
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 318
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 313
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 282
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 278
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 269
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 269
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 252
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 248
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 244
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 234
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 219
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 212
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 205
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 198
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 198
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 186
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 181
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 172
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors 170
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 167
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 164
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 163
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 149
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 143
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 119
Totale 6.884
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.202
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.202
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021375 0 0 0 0 0 76 50 59 40 59 32 59
2021/2022353 27 33 24 13 30 40 20 25 18 39 32 52
2022/2023849 83 244 88 88 60 114 8 58 52 20 19 15
2023/2024523 16 18 24 25 58 169 101 12 36 9 2 53
2024/20251.115 67 114 57 54 100 42 75 31 134 181 90 170
2025/20261.628 362 137 226 384 386 133 0 0 0 0 0 0
Totale 6.884